Bumper Offer - Urjas oil Just @ Rs. 1
Zifi 50 Dry Syrup 30ml is a prescription medicine that is available as a Syrup. It is typically used for the treatment of Ear Infection, Tonsillitis, Bronchitis. Other than this, Zifi 50 Dry Syrup 30ml has some other therapeutic uses, which have been discussed ahead.
The optimal dosage of Zifi 50 Dry Syrup 30ml is largely dependent on the individual's body weight, medical history, gender and age. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. This information has been provided in detail in the dosage section.
Besides the aforementioned side effects, there are other adverse effects of Zifi 50 Dry Syrup 30ml as well, which are listed below. Such side effects of Zifi 50 Dry Syrup 30ml normally do not last long and go away once the treatment is completed. If, however, they worsen or do not go away, please speak with your physician.
It is also important to note that Zifi 50 Dry Syrup 30ml has a Safe effect for pregnant women and Safe effect on lactating mothers. Warnings related to Zifi 50 Dry Syrup 30ml's effects on the liver, heart and kidney, if any, have been listed below.
Some other conditions that can be affected by Zifi 50 Dry Syrup 30ml are listed in the contraindications section below.
Drug reaction of Zifi 50 Dry Syrup 30ml with other medicines has been reported. Refer to the list below for further details.
Along with the above-mentioned precautions, remember that taking Zifi 50 Dry Syrup 30ml is considered not safe while driving, and is not addictive.
Zifi 50 Dry Syrup 30ml is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
Is the use of Zifi 50 Dry Syrup 30ml safe for pregnant women?
Zifi is safe to take during pregnancy.
Is the use of Zifi 50 Dry Syrup 30ml safe during breastfeeding?
Zifi is completely safe for breastfeeding women.
What is the effect of Zifi 50 Dry Syrup 30ml on the Kidneys?
Zifi has very mild side effects on the kidneys.
What is the effect of Zifi 50 Dry Syrup 30ml on the Liver?
Zifi is not harmful for the liver.
What is the effect of Zifi 50 Dry Syrup 30ml on the Heart?
You can take Zifi without any fear of damage to the heart.
Zifi 50 Dry Syrup 30ml should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Zifi 50 Dry Syrup 30ml unless your doctor advises you to do so -
Is this Zifi 50 Dry Syrup 30ml habit forming or addictive?
No, you will not get addicted to Zifi 50 Dry Syrup 30ml.
Is it safe to drive or operate heavy machinery when consuming?
No, you should not drive or operate heavy machinery after taking Zifi 50 Dry Syrup 30ml as you may feel sleepy.
Is it safe?
Zifi 50 Dry Syrup 30ml is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
No, the use of Zifi 50 Dry Syrup 30ml in mental disorders is not effective.
Interaction between Food and Zifi 50 Dry Syrup 30ml
Taking Zifi 50 Dry Syrup 30ml with food does not cause any problems.
Interaction between Alcohol and Zifi 50 Dry Syrup 30ml
It is difficult to say anything about the effect of Zifi 50 Dry Syrup 30ml and alcohol. No research has been done on this yet.
This medicine data has been created by -
References
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 839
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)